Indicated to address blood sugar levels in type 2 diabetes to support metabolic health and mitigate the risk of diabetes-related complications in adults.
Mechanism of Action
Linagliptin blocks the enzyme DPP-4, which normally breaks down natural 'incretin' hormones. By keeping these hormones active longer, the body produces more insulin after meals and less sugar in the liver, lowering blood glucose levels.
Route of Administration
Oral
Onset Time
1.5 hours
Duration
24 hours
Contraindications
History of serious hypersensitivity to linagliptin, Type 1 diabetes, Diabetic ketoacidosis
Severe Adverse Events
Acute pancreatitis, Heart failure, Bullous pemphigoid (skin blistering), Severe allergic reactions, Severe joint pain
Common Side Effects
Mild headache, Cough
Uncommon Side Effects
Nasopharyngitis (cold symptoms), Joint pain, Diarrhea, Hypoglycemia (if used with insulin)
Information for Tradjenta is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
